AZD5335

DRUG3 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Advanced Platinum-resistant Epithelial Ovarian CancerEpithelial Ovarian CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal

Phase 1

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

RecruitingNCT07402915

AstraZenecaFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal

Start: 2026-01-26End: 2027-10-15Target: 24Updated: 2026-07-07

Phase 3

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

RecruitingNCT07218809

AstraZenecaEpithelial Ovarian Cancer

Start: 2025-12-29End: 2030-05-27Target: 1100Updated: 2026-01-16

Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Not yet recruitingCTIS2025-520466-22-00

AstraZeneca ABAdvanced Platinum-resistant Epithelial Ovarian Cancer

Target: 46Updated: 2026-03-27